CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors
Xupeng Ge(Massachusetts General Hospital), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Megan Sykes(Columbia University Irving Medical Center), Julia A. Brown(Cornell University)
Cited by 43
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
|New England Journal of Medicine|2008|972